Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain

Virology Journal

Volumn 9, Issue , 2012, Pages

  Shim, Byoung Shik ^a,b   Stadler, Konrad ^a   Nguyen, Huan Huu ^a   Yun, Cheol Heui ^b   Kim, Dong Wook ^c   Chang, Jun ^d   Czerkinsky, Cecil ^a   Song, Man Ki ^a  

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

^c Hanyang University   (South Korea)

^d Ewha Womans University   (South Korea)

Author keywords

IgA; Mucosa; Recombinant adenovirus; Severe acute respiratory syndrome; Sublingual administration; T cell

Indexed keywords

ADENOVIRUS VECTOR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BRAIN; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORONAVIRUS; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; OLFACTORY BULB; RESPIRATORY SYSTEM; SEVERE ACUTE RESPIRATORY SYNDROME;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, VIRAL; BRAIN; FEMALE; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

ADENOVIRIDAE; CORONAVIRUS; MUS; SARS CORONAVIRUS;

EID: 84866485976     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-215     Document Type: Article

References (54)

1. [Mucosal immunity with implications for use in developing a new generation of vaccines]. Osek J, Truszczynski M, Postepy Hig Med Dosw 1995 49 469 486 8657643
2. Mucosal immunity and vaccines. Holmgren J, Czerkinsky C, Nat med 2005 11 45 S53 10.1038/nm1213 15812489 (Pubitemid 40562303)
3. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. See R, Zakhartchouk A, Petric M, Lawrence D, Mok C, Hogan R, Rowe T, Zitzow L, Karunakaran K, Hitt M, J Gen Virol 2006 87 641 650 10.1099/vir.0.81579-0 16476986
4. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KH, J Infect Dis 2005 192 1628 1633 10.1086/491739 16206078 (Pubitemid 41504699)
5. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR, Vaccine 2002 20 2431 2438 10.1016/S0264-410X(02)00155-X 12057597 (Pubitemid 34615580)
6. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR, J Immunol 2000 165 4778 4782 11045998
7. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. Lemiale F, Kong W, Akyurek L, Ling X, Huang Y, Chakrabarti B, Eckhaus M, Nabel G, J Virol 2003 77 10078 10087 10.1128/JVI.77.18.10078-10087. 2003 12941918 (Pubitemid 37122089)
8. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Tims T, Briggs DJ, Davis RD, Moore SM, Xiang Z, Ertl HC, Fu ZF, Vaccine 2000 18 2804 2807 10.1016/S0264-410X(00)00088-8 10812222 (Pubitemid 30254466)
9. Development of a preventive vaccine for Ebola virus infection in primates. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ, Nature 2000 408 605 609 10.1038/35046108 11117750
10. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Xiang ZQ, Yang Y, Wilson JM, Ertl HC, Virology 1996 219 220 227 10.1006/viro.1996.0239 8623532 (Pubitemid 26180398)
11. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Liu RY, Wu LZ, Huang BJ, Huang JL, Zhang YL, Ke ML, Wang JM, Tan WP, Zhang RH, Chen HK, et al. Virus Res 2005 112 24 31 10.1016/j.virusres.2005.02.009 16022898 (Pubitemid 40966771)
12. Oral adenoviral-based vaccines: historical perspective and future opportunity. Tucker S, Tingley D, Scallan C, Expert Rev Vaccines 2008 7 25 31 10.1586/14760584.7.1.25 18251691 (Pubitemid 351357964)
13. Enteric immunization with live adenovirus type 21 vaccine II. systemic and local immune responses following immunization. Scott R, Dudding B, Romano S, Russell P, Infect Immun 1972 5 300 304 4629075
14. T-cell immunity generated by recombinant adenovirus vaccines. Yang T, Millar J, Grinshtein N, Bassett J, Finn J, Bramson J, Expert Rev Vaccines 2007 6 347 356 10.1586/14760584.6.3.347 17542750 (Pubitemid 46911598)
15. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Hsu K, Lubeck M, Bhat B, Bhat R, Kostek B, Selling B, Mizutani S, Davis A, Hung P, Vaccine 1994 12 607 612 10.1016/0264-410X(94)90264- X 8085377 (Pubitemid 24153526)
16. Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Shanley J, Wu C, Vaccine 2005 23 996 1003 10.1016/j.vaccine.2004.07. 041 15620472 (Pubitemid 40037648)
17. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. Shi Z, Zeng M, Yang G, Siegel F, Cain L, Van Kampen K, Elmets C, Tang D, J Virol 2001 75 11474 11482 10.1128/JVI.75.23.11474-11482.2001 11689629 (Pubitemid 33063239)
18. Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters. Morin J, Lubeck M, Barton J, Conley A, Davis A, Hung P, Proc Natl Acad Sci USA 1987 84 4626 4630 10.1073/pnas.84.13.4626 2955413
19. High-level eucaryotic in vivo expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system. Alkhatib G, Briedis D, J Virol 1988 62 2718 2727 3292790
20. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. Buge S, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller C, Lubeck M, Udem S, Eldridge J, J Virol 1997 71 8531 8541 9343211 (Pubitemid 27446435)
21. New approaches to the prevention and eradication of rabies. Dietzschold B, Faber M, Schnell MJ, Expert Rev Vaccines 2003 2 399 406 10.1586/14760584.2.3. 399 12903805 (Pubitemid 36713366)
22. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP, J Infect Dis 2007 196 Suppl 2 413 S420 17940978
23. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. Xiang Z, Li Y, Gao G, Wilson JM, Ertl HC, J Immunol 2003 171 4287 4293 14530353 (Pubitemid 37238707)
24. Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector. Damjanovic D, Zhang X, Mu J, Fe Medina M, Xing Z, Genet Vaccines Ther 2008 6 5 10.1186/1479-0556-6-5 18261231 (Pubitemid 351338738)
25. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Davidson B, Allen E, Kozarsky K, Wilson J, Roessler B, Nat Genet 1993 3 219 223 10.1038/ng0393-219 8387378 (Pubitemid 23096556)
26. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. Burastero S, Mistrello G, Falagiani P, Paolucci C, Breda D, Roncarolo D, Zanotta S, Monasterolo G, Rossi R, Ann Allergy Asthma Immunol 2008 100 343 350 10.1016/S1081-1206(10)60597-2 18450120 (Pubitemid 351520326)
27. Immunologic responses to sublingual allergen immunotherapy. Akdis M, Clin Allergy Immunol 2008 21 71 86 18828499
28. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C, J Allergy Clin Immunol 2007 120 707 713 10.1016/j.jaci.2007.06.013 17681368 (Pubitemid 47320765)
29. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, Stefani E, Tierno E, Int J Immunopathol Pharmacol 2003 16 73 79 12578735 (Pubitemid 36268144)
30. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Cuburu N, Kweon M, Song J, Hervouet C, Luci C, Sun J, Hofman P, Holmgren J, Anju re F, Czerkinsky C, Vaccine 2007 25 8598 8610 10.1016/j.vaccine.2007.09.073 17996991 (Pubitemid 350192038)
31. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Song J, Nguyen H, Cuburu N, Horimoto T, Ko S, Park S, Czerkinsky C, Kweon M, Proc Natl Acad Sci USA 2008 105 1644 1649 10.1073/pnas.0708684105 18227512 (Pubitemid 351346568)
32. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: Association with mucoadhesion and efficient penetration of the sublingual barrier. Domm W, Brooks L, Chung HL, Feng C, Bowers WJ, Watson G, McGrath JL, Dewhurst S, Vaccine 2011 29 7080 7089 10.1016/j.vaccine.2011.07.008 21801777
33. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting ad5 immunity. Appledorn DM, Aldhamen YA, Godbehere S, Seregin SS, Amalfitano A, Clin Vaccine Immunol 2011 18 150 160 10.1128/CVI.00341-10 21084461
34. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A, Nat med 2004 10 871 875 10.1038/nm1080 15247913 (Pubitemid 39070862)
35. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh W, Zaki S, Murphy B, J Virol 2004 78 3572 3577 10.1128/JVI.78.7.3572-3577.2004 15016880 (Pubitemid 38568299)
36. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins P, Murphy B, Subbarao K, Moss B, Proc Natl Acad Sci USA 2004 101 6641 6646 10.1073/pnas.0401939101 15096611 (Pubitemid 38586027)
37. Immunization without needles. Mitragotri S, Nat Rev Immunol 2005 5 905 916 10.1038/nri1728 16239901 (Pubitemid 41746760)
38. Mucosal vaccines: the promise and the challenge. Neutra M, Kozlowski P, Nat Rev Immunol 2006 6 148 158 10.1038/nri1777 16491139 (Pubitemid 43361590)
39. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Yang Z, Kong W, Huang Y, Roberts A, Murphy B, Subbarao K, Nabel G, Nature 2004 428 561 564 10.1038/nature02463 15024391 (Pubitemid 38480539)
40. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. Lee J, Poo H, Han D, Hong S, Kim K, Cho M, Kim E, Sung M, Kim C, J Virol 2006 80 4079 4087 10.1128/JVI.80.8.4079-4087.2006 16571824
41. Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. Williamson J, Stohlman S, J Virol 1990 64 4589 4592 2166833 (Pubitemid 20279878)
42. CD8+ T cell effector mechanisms in resistance to infection. Harty J, Tvinnereim A, White D, Annu Rev Immunol 2000 18 275 308 10.1146/annurev.immunol. 18.1.275 10837060 (Pubitemid 30365382)
43. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Zhi Y, Kobinger G, Jordan H, Suchma K, Weiss S, Shen H, Schumer G, Gao G, Boyer J, Crystal R, Virology 2005 335 34 45 10.1016/j.virol.2005.01.050 15823604 (Pubitemid 40489050)
44. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16L1 protein with adjuvants. Cho H, Kim J, Lee Y, Kim J, Kim Y, Chun T, Oh Y, Vaccine 2010 28 2598 2606 10.1016/j.vaccine.2010.01.013 20116467
45. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YYS, Holmgren J, Stadler K, Schiller JT, Anjuere F, Czerkinsky C, J Immunol 2009 183 7851 7859 10.4049/jimmunol.0803740 19933861
46. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, Vimeux L, Maranon C, Czerkinsky C, Vaccine 2010 28 5582 5590 10.1016/j.vaccine.2010.06.033 20600505
47. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S, Nat Rev Microbiol 2009 7 226 236 10.1038/nrmicro2090 19198616
48. Th2 predominance and CD8+ memory T cell depletion in patients with severe acute respiratory syndrome. Huang J, Huang J, Duan Z, Wei J, Min J, Luo X, Li J, Tan W, Wu L, Liu R, Microbes Infect 2005 7 427 436 10.1016/j.micinf.2004.11. 017 15784184 (Pubitemid 40603441)
49. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. See R, Petric M, Lawrence D, Mok C, Rowe T, Zitzow L, Karunakaran K, Voss T, Brunham R, Gauldie J, J Gen Virol 2008 89 2136 2146 10.1099/vir.0.2008/001891-0 18753223
50. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Kobinger G, Figueredo J, Rowe T, Zhi Y, Gao G, Sanmiguel J, Bell P, Wivel N, Zitzow L, Flieder D, Vaccine 2007 25 5220 5231 10.1016/j.vaccine.2007.04.065 17559989 (Pubitemid 46915465)
51. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA, Lifton MA, Chakrabarti BK, Xu L, Nabel GJ, J Virol 2003 77 8729 8735 10.1128/JVI.77.16.8729-8735.2003 12885892 (Pubitemid 36936084)
52. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. Lewis D, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, PLoS One 2009 4 6999 10.1371/journal.pone.0006999 19756141
53. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Hamilton MA, Russo RC, Thurston RV, Environ Sci Technol 1977 11 714 719 10.1021/es60130a004 (Pubitemid 8167560)
54. Coordinate regulation of complex T cell populations responding to bacterial infection. Busch DH, Pilip IM, Vijh S, Pamer EG, Immunity 1998 8 353 362 10.1016/S1074-7613(00)80540-3 9529152 (Pubitemid 28188895)